All In Biotech

Drug Trial Radar · NCT01543178

Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study

A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Last checked: Nov 20, 2026Latest source record: Dec 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,583 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,583

Actual

Start

Feb 2012

Primary completion

Jun 2014

Study completion Jun 2014

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Mar 2, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the effectiveness and safety of repeat treatment with rifaximin 550 mg three times a day in patients with IBS with diarrhea who respond to initial treatment of rifaximin 550 mg three times a day.

Conditions

  • Irritable Bowel Syndrome With Diarrhea

Interventions

  • open-label rifaximinDrug

    550 mg three times a day (open-label)

  • double-blind placeboDrug

    3 times a day (double-blind)

  • double-blind rifaximinDrug

    550 mg three times a day (double-blind)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Repeat Treatment RespondersTime frame: 4-week treatment-free follow-up in double-blind repeat treatment phase.

Locations

296 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    Anniston, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Dothan, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Montgomery, Alabama

  • Site not named

    Montgomery, Alabama

  • Site not named

    Selma, Alabama

  • Site not named

    Chandler, Arizona

  • Site not named

    Peoria, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Tempe, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Jonesboro, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    North Little Rock, Arkansas

  • Site not named

    Sherwood, Arkansas

  • Site not named

    Anaheim, California

  • Site not named

    Artesia, California

  • Site not named

    Carlsbad, California

  • Site not named

    Chula Vista, California

  • Site not named

    Chula Vista, California

  • Site not named

    Concord, California

  • Site not named

    Encinitas, California

  • Site not named

    Encino, California

  • Site not named

    Escondido, California

  • Site not named

    Garden Grove, California

  • Site not named

    Garden Grove, California

  • Site not named

    Garden Grove, California

  • Site not named

    Glendale, California

  • Site not named

    Huntington Beach, California

  • Site not named

    La Mesa, California

  • Site not named

    La Mirada, California

Showing 40 of 296 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.